Isis and antisense face crucial test without Novartis

被引：0

|

作者：

Alan Dove

机构：

来源：

Nature Biotechnology | 2000年 / 18卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：19 / 19

相关论文

共 50 条

[31] ISIS 3521/CGP 64128A - Antisense to protein kinase C
Dorr, FA
Sikic, BI
Nemunaitis, J
Eckhardt, G
Yuen, AR
EUROPEAN JOURNAL OF CANCER, 1997, 33 : 115 - 115
[32] Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development
Holmlund, JT
Monia, BP
Kwoh, TJ
Dorr, FA
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1999, 1 (03) : 372 - 385
[33] A CRUCIAL TEST FOR EUROPE
HILSE, G
FLEISCHWIRTSCHAFT, 1989, 69 (06): : 971 - 971
[34] A CRUCIAL TEST FOR YUGOSLAVIA
BREY, T
OSTEUROPA, 1989, 39 (06): : 568 - 581
[35] DRUG DEVELOPMENT Novartis, Mirati test KRas inhibitor
Cross, Ryan
CHEMICAL & ENGINEERING NEWS, 2019, 97 (28) : 15 - 15
[36] Isis-301012 - Antisense inhibitor of apolipoprotein B treatment of lipoprotein disorders
Wang, Y.
DRUGS OF THE FUTURE, 2007, 32 (08) : 699 - 702
[37] Novartis must face kickback lawsuit over "sham" speaker events
McCarthy, Michael
BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[38] Isis lawsuit threatens Santaris's antisense deals and questions research exemption
不详
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) : 804 - 804
[39] Phase 1 study of an ICAM-1 antisense oligonucleotide (ISIS 2302)
Shanahan, W
Glover, J
Mant, T
Amin, D
Leeds, J
Zuckerman, J
Levin, A
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII80 - PII80
[40] A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer
Tolcher, AW
Reyno, L
Venner, PM
Ernst, SD
Moore, M
Geary, RS
Chi, K
Hall, S
Walsh, W
Dorr, A
Eisenhauer, E
CLINICAL CANCER RESEARCH, 2002, 8 (08) : 2530 - 2535

← 1 2 3 4 5 →